Failed clinical trials can be fatal for small biotechs that don’t have the backing of big pharma, and even having to alter plans can be prohibitively costly. As part of a series on trends in oncology ...

Patients could play a key role in generating the data required to make Europe's Adaptive Licensing a success. The timing of patient access to new medicines has always been one of the major conundrums ...

Andrew Lo, a professor of finance at the Massachusetts Institute of Technology, dialled in from Boston to talk about regulation, markets and the future of machine learning. Lo pioneered the adaptive ...

Adaptive Biotechnologies has seen its fair value estimate climb from $16.00 to $17.14 per share, reflecting a moderate revision upward by market analysts. This change comes as experts weigh Adaptive’s ...